NCT00424892

Brief Summary

The primary objective is to evaluate the long-term safety of desvenlafaxine succinate sustained-release (DVS SR) during open-label treatment in adult outpatients with fibromyalgia syndrome.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
600

participants targeted

Target at P75+ for phase_2

Geographic Reach
1 country

59 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 18, 2007

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 22, 2007

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2007

Completed
Last Updated

December 6, 2007

Status Verified

December 1, 2007

First QC Date

January 18, 2007

Last Update Submit

December 4, 2007

Conditions

Outcome Measures

Primary Outcomes (1)

  • The following assessments are made to assess safety: physical examination, vital signs, standard 12-lead ECG, laboratory determinations, adverse events and serious adverse events, BDI-II.

Secondary Outcomes (1)

  • Pain score on the Numeric Rating Scale, FIQ score, PGIC, MAF, CGIC, Patient Global Symptom Rating and Physician Global Rating, MTPS, MOS-Sleep Measure.

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Outpatients who have completed double-blind treatment in study 3151A4-327 for fibromyalgia Syndrome with no major protocol violations and no events that would preclude the patient's entry into the long-term open-label study.
  • Women of childbearing potential must have a negative serum pregnancy test result at study start.

You may not qualify if:

  • Presence of any new/and or clinically important medical condition that might compromise patient's safety.
  • Use of prohibited treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (59)

Unknown Facility

Huntsville, Alabama, 35801, United States

Location

Unknown Facility

Mobile, Alabama, 36608, United States

Location

Unknown Facility

Phoenix, Arizona, 85016, United States

Location

Unknown Facility

Anaheim, California, 92801, United States

Location

Unknown Facility

Sacramento, California, 95825, United States

Location

Unknown Facility

San Diego, California, 92108, United States

Location

Unknown Facility

Santa Ana, California, 92705, United States

Location

Unknown Facility

Walnut Creek, California, 94598, United States

Location

Unknown Facility

Denver, Colorado, 80218, United States

Location

Unknown Facility

Cromwell, Connecticut, 06416, United States

Location

Unknown Facility

Brooksville, Florida, 34613, United States

Location

Unknown Facility

DeLand, Florida, 32720, United States

Location

Unknown Facility

Delray Beach, Florida, 33484, United States

Location

Unknown Facility

Jacksonville, Florida, 32216, United States

Location

Unknown Facility

Miami, Florida, 33143, United States

Location

Unknown Facility

Palm Beach Gardens, Florida, 33418, United States

Location

Unknown Facility

Pembroke Pines, Florida, 33026, United States

Location

Unknown Facility

St. Petersburg, Florida, 33709, United States

Location

Unknown Facility

Sunrise, Florida, 33351, United States

Location

Unknown Facility

Tamarac, Florida, 33321, United States

Location

Unknown Facility

Tampa, Florida, 33606, United States

Location

Unknown Facility

Atlanta, Georgia, 30342, United States

Location

Unknown Facility

Decatur, Georgia, 30033, United States

Location

Unknown Facility

Smyrna, Georgia, 30080, United States

Location

Unknown Facility

Chicago, Illinois, 60611, United States

Location

Unknown Facility

Chicago, Illinois, 60612, United States

Location

Unknown Facility

Indianapolis, Indiana, 46202, United States

Location

Unknown Facility

Lexington, Kentucky, 40509, United States

Location

Unknown Facility

Lexington, Kentucky, 40536, United States

Location

Unknown Facility

Rockville, Maryland, 20852, United States

Location

Unknown Facility

Boston, Massachusetts, 02115, United States

Location

Unknown Facility

Newton, Massachusetts, 02462, United States

Location

Unknown Facility

Lansing, Michigan, 48910, United States

Location

Unknown Facility

Kansas City, Missouri, 64114, United States

Location

Unknown Facility

St Louis, Missouri, 63117, United States

Location

Unknown Facility

Las Vegas, Nevada, 89106, United States

Location

Unknown Facility

Clementon, New Jersey, 08021, United States

Location

Unknown Facility

Raleigh, North Carolina, 27612, United States

Location

Unknown Facility

Cincinnati, Ohio, 45219, United States

Location

Unknown Facility

Dayton, Ohio, 45408, United States

Location

Unknown Facility

Oklahoma City, Oklahoma, 73103, United States

Location

Unknown Facility

Oklahoma City, Oklahoma, 73112, United States

Location

Unknown Facility

Tulsa, Oklahoma, 74104, United States

Location

Unknown Facility

Duncansville, Pennsylvania, 16635, United States

Location

Unknown Facility

Harleysville, Pennsylvania, 19438, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19149, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19152, United States

Location

Unknown Facility

Sellersville, Pennsylvania, 18960, United States

Location

Unknown Facility

West Reading, Pennsylvania, 19611, United States

Location

Unknown Facility

Warwick, Rhode Island, 02886, United States

Location

Unknown Facility

Charleston, South Carolina, 29407, United States

Location

Unknown Facility

Summerville, South Carolina, 29485, United States

Location

Unknown Facility

Bristol, Tennessee, 37620, United States

Location

Unknown Facility

Chattanooga, Tennessee, 37404, United States

Location

Unknown Facility

Memphis, Tennessee, 38119, United States

Location

Unknown Facility

Austin, Texas, 78756, United States

Location

Unknown Facility

Dallas, Texas, 75231, United States

Location

Unknown Facility

San Antonio, Texas, 78205, United States

Location

Unknown Facility

Middleton, Wisconsin, 53562, United States

Location

MeSH Terms

Conditions

Fibromyalgia

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System Diseases

Study Officials

  • Medical Monitor

    Wyeth is now a wholly owned subsidiary of Pfizer

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

January 18, 2007

First Posted

January 22, 2007

Study Completion

June 1, 2007

Last Updated

December 6, 2007

Record last verified: 2007-12

Locations